Please use the attached document to answer the following questions: Drug Trials in Developing Countries (India) 8.7, pgs. 263-265,: ? What are the barriers to obtaining true informed consent from these patients, and what can be done to overcome these barriers? 2. What are the ethical implications of tying a researchers compensation to the number of subjects enrolled? Should this practice be permitted? 3. Are multinational pharmaceutical companies that benefit from cost-effective drug trials in developing countries obligated to improve the lives of people living in those countries? 4. Who should be held responsible for adverse events due to a drug trial conducted by a multinational company in a country where there is limited health insurance, no social security, and poor enforcement of regulations? What international or grassroots efforts might help ensure accountability for adverse events?
Use the order calculator below and get started! Contact our live support team for any assistance or inquiry.[order_calculator]